



House of Commons

Hon. Navdeep Singh Bains, P.C., M.P.
Mississauga – Brampton South



OTTAWA

February 7, 2007

Mr. Douglas Clark
Director, Patent Policy Directorate
Industry Canada
235 Queen Street
Ottawa, ON K1A 0H5
clark.douglas@ic.gc.ca

Ms. Brigitte Zirger
Director, Therapeutic Products Directorate
Health Canada
1600 Scott Street
Ottawa, ON K1A 0K9
Brigitte.Zirger@hc-sc.gc.ca

Re: Review of Canada's Access to Medicines Regime

Dear Mr. Clark and Ms. Zirger:

I am writing in response to the request for comment on November 24, 2006 concerning *Canada's Access to Medicines Regime (CAMR)*.

I wish to draw your attention to documents submitted by domestic and international stakeholders on the review of the CAMR. As you know, the innovative pharmaceutical industry in Canada, which has a significant presence here in Ontario and the GTA, is making a major contribution to the fight against disease in the developing world. I was pleased to learn of these contributions by way of the attached submissions. I also note their strong and helpful partnerships with Health Partners International (HPIC) and other such organizations.

Ottawa
Room 776 Confederation Bldg.
Ottawa, ON K1A 0A6
Tel: (613) 995-7784
Fax: (613) 996-9817



www.navdeepbains.ca

Constituency
6660 Kennedy Road, Suite 215 A
Mississauga, ON L5T 2M9
Tel: (905) 795-5220
Fax: (905) 795-5252
E-mail: bainsn1@parl.gc.ca

GlaxoSmithKline (GSK) has a major production facility in my riding, which I have visited. GSK's 2,800 Canadian employees produce medicines and vaccines that are crucial in the fight against diseases such as HIV/AIDS and Malaria. Approximately 80 per cent of production from the company's plant in Mississauga, Ontario is exported to more than 120 countries worldwide, including many developing countries.

I feel strongly that, on their own, modifications to the CAMR will only deliver limited value to patients in developing countries. The fact is that access to medicines is not the sole—or, in some countries, even the most significant—health-care challenge facing the developing world. Medicines cannot do their job effectively if patients do not also have access to safe drinking water, sufficient food, or primary health care. I would encourage the government to take a broader look at the new and emerging needs of the developing world.

In my role as International Trade Critic with a keen interest in aid and development, I would urge the government not to weaken the anti-diversion and other necessary measures contained in the legislation.

The federal government should not consider CAMR in isolation from other policies. The health-care challenges of the developing world are broad, and Canadian aid policy should be as well.

Sincerely,



Hon. Navdeep Bains, M.P., P.C.
Critic for International Trade

BN/pc